Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect

被引:185
作者
Vincent, L
Chen, W
Hong, L
Mirshahi, F
Mishal, Z
Mirshahi-Khorassani, T
Vannier, JP
Soria, J
Soria, C
机构
[1] Lab DIFEMA, UFR Med & Pharm Rouen, F-76183 Rouen, France
[2] Hop St Louis, INSERM, U553, Paris, France
[3] Hotel Dieu, Biochim Lab, Paris, France
[4] Hotel Dieu, EMI 99 12, Paris, France
关键词
anti-angiogenesis; migration; HMG-CoA reductase inhibitor; cerivastatin; RhoA; Ras;
D O I
10.1016/S0014-5793(01)02337-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent studies have suggested that inhibitors of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (statins) can play a role in protection against vascular risk, which is independent of cholesterol reduction. It could act by inhibiting the synthesis of isoprenoids (farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP)), which are respectively essential for membrane attachment and biological activity of GTPases Ras and RhoA. This study demonstrates that a statin (cerivastatin) inhibits angiogenesis, This effect was due to a decrease in endothelial cell locomotion which was reversed by GGPP, It was mainly related to delocalization of RhoA from cell membrane to cytoplasm, responsible for the disorganization of actin stress fibers. Furthermore, a decrease in MMP-2 secretion, involved in cell invasion, mas also observed. This effect is rather due to Ras inhibition as it was reversed by FPP, This antiangiogenic activity could explain the beneficial effect of statins on atherosclerosis and on cancer prevention as shown by clinical studies. (C) 2001 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
引用
收藏
页码:159 / 166
页数:8
相关论文
共 28 条
[1]   Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase [J].
Adam, L ;
Vadlamudi, R ;
Kondapaka, SB ;
Chernoff, J ;
Mendelsohn, J ;
Kumar, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (43) :28238-28246
[2]   HMEC-1 - ESTABLISHMENT OF AN IMMORTALIZED HUMAN MICROVASCULAR ENDOTHELIAL-CELL LINE [J].
ADES, EW ;
CANDAL, FJ ;
SWERLICK, RA ;
GEORGE, VG ;
SUMMERS, S ;
BOSSE, DC ;
LAWLEY, TJ .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1992, 99 (06) :683-690
[3]   Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures [J].
Axel, DI ;
Riessen, R ;
Runge, H ;
Viebahn, R ;
Karsch, KR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2000, 35 (04) :619-629
[4]   Signaling angiogenesis via p42/p44 MAP kinase and hypoxia [J].
Berra, E ;
Milanini, J ;
Richard, DE ;
Le Gall, M ;
Viñals, F ;
Gothié, E ;
Roux, D ;
Pagès, G ;
Pouysségur, J .
BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) :1171-1178
[5]   Ongoing trials with matrix metalloproteinase inhibitors [J].
Brown, PD .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (09) :2167-2177
[6]   Isoprenoid-mediated inhibition of mevalonate synthesis: Potential application to cancer [J].
Elson, CE ;
Peffley, DM ;
Hentosh, P ;
Mo, HB .
PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY AND MEDICINE, 1999, 221 (04) :294-311
[7]   Oncogenic Ha-Ras-induced signaling activates NF-kappa B transcriptional activity, which is required for cellular transformation [J].
Finco, TS ;
Westwick, JK ;
Norris, JL ;
Beg, AA ;
Der, CJ ;
Baldwin, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (39) :24113-24116
[8]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[9]   Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase Akt signal transduction pathway -: Requirement for Flk-1/KDR activation [J].
Gerber, HP ;
McMurtrey, A ;
Kowalski, J ;
Yan, MH ;
Keyt, BA ;
Dixit, V ;
Ferrara, N .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) :30336-30343
[10]   Target molecules for anti-angiogenic therapy: from basic research to clinical trials [J].
Hagedorn, M ;
Bikfalvi, A .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 34 (02) :89-110